Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for refractory cancer pain
NCT03936205Phase 3Completed
- Sponsor
- Hôtel-Dieu de France
- Start
- Aug 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of dexmedetomidine in cancer pain, sponsored by Hôtel-Dieu de France. Started Aug 2016; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT03936205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03936205.